[1] KAWASHIMA Y. Nanoparticulate systems for improved drug delivery[J] . Adv Drug Deliv Rev，2001，47 (1)：1-2. [2] FERRARI M. Cancer nanotechnology： opportunities and challenges[J] . Nat Rev Cancer，2005，5(3)： 161-171. [3] HARISINGHANI M G，BARENTSZ J，HAHN P F，et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer[J] . N Engl J Med，2003，348(25)：2491-2499. [4] KOBAYASHI O，ONODERAS S，RINO Y，et al. Evaluation of medicinal lymph node dissection in advanced gastric cancer[J] . Nippon Geka Gakkai Zasshi，1994，95(12)：860-865. [5] LI C Y，LI S B. Studies on drug carriers with affinity to lymph and prospect[J] . Chin J Mod Appl Pharm(中国现代应用药学杂志)，2001，18(6)：426-428. [6] SWARTZ M A. The physiology of the lymphatic system[J] . Adv Drug Deliv Rev，2001，50(1-2)：3-20. [7] OHHASHI T，MIZUNO R，IKOMI F T，et al. Current topics of physiology and pharmacology in the lymphatic system[J] . Pharmacol Ther，2005，105(2)： 165-188. [8] LIU Z Y. Basis and Clinical Study of Lymph(淋巴的基础和临床)[M] . Beijing：Science Press，2003：13-14. [9] HE J，HOU S X，FENG J F. Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles[J] . China J Chin Mater Med(中国中药杂志)，2005，30(21)：1651-1653. [10] ERMAK T H，DOUGHERTY E P，BHAGAT H R，et al. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells[J] . Cell Tissue Res，1995，279(2)：433-436. [11] PAN Y，XU H，ZHAO H Y，et al. Study on preparation and oral efficacy of insulin-loaded poly(lactic-co-glycolic acid)nanoparticles[J] . Acta Pharm Sin(药学学报)，2002，37(7)：374-377. [12] SCHIPPER G M，VARUM K M，STENBERG P. Chitosan asabsorption enhancers of poorly absorbable drugs 3：influenceof mucuson absorption enhancement[J] . Eur J Pharm Sci，1999，8(2)：335-343. [13] WASAN K M. The role of lymphatic transport in enhancing oral protein and peptide drug delivery[J] . Drug Dev Ind Pharm，2002，28(9)：1047-1058. [14] HAWLEY A E，ILLUM L，DAVIS S S. The effect of lymphatic oedema on the uptake of colloids to the lymph nodes[J] . Biopharm Drug Dispos，1998，19(3)： 193-197. [15] HOBSON P，BARNFIELD C，BARNES A，et al. Mucosal immunization with DNA vaccines[J] . Methods，2003，31(3)：217-224. [16] WU H Y. Nasal lymphoid tissue，intranasal immunization，and compartmentalization of the common mucosal immune system[J] . Immunol Res，1997，16(2)：187-201. [17] YU F. Nasal associated lymphatic tissue and nasal immunization[J] . Foreign Med Sci（Parsitic Diseases）(国外医学·寄生虫病分册)，2003，6(26)：265-268. [18] NARDELLI-HAEFLIGER D，BENYACOUB J，LEMOINE R，et al. Nasal vaccination with attenuated salmonella typhimurium strains expressing the hepatitis B nucleocapsid： dose response analysis[J] . Vaccine，2001，19 (20-22)：2854-2861. [19] CRYAN S A. Carrier-based strategies for targeting protein and peptide drugs to the lungs[J] . AAPS J，2005，7(1)：20-41. [20] LIU G J. Pharmaceutics(药剂学)[M] . Edi. 2. Beijing：People’s Medical Publishing House，1985：1110-1112. [21] PAPISOV M I，WEISSLEDER R，SCHAFFER B B，et al. Intravenous carriers for drug delivery to lymph nodes[J] . J Controlled Release，1994，28(1-3)：293-295. [22] YANG L Z，SUN L，ZHANG Y G. Distribution，migration and excretion of bio-inert nano-particles in vivo[J] . Lett Biotechnol(生物技术通讯)，2005，16(5)：525-527. [23] FLESSNER M，PARKER R，SIEBER S. Peritoneal lymphatic uptake of fibrinogen and erythrocytes in the rats[J] . Am J Physiol，1983，244(1)：89-96. [24] BETTENDORF U. Electromicroscopic studies on the peritoneal resorption of intraperitoneally injected latex particles via the diaphragmatic lymphatics[J] . Lymphology，1979，12(2)：66-70. [25] HIRANO K，HUNT C A，STRUBBE A，et al. Lymphatic transport of liposome encapsulated drugs following intraperitoneal administration-effect of liposome composition[J] . Pharm Res，1985，2(6)：271-278. [26] SADZUKA Y，HIROTA S，SONOBE T. Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination[J] . Toxicol Lett，2000，116(1-2)：51-59. [27] OUSSOREN C，STORM G. Liposomes to target the lymphatics by subcutaneous administration[J] . Adv Drug Deliv Rev，2001，50(1-2)：143-156. [28] ALLEN T M，HANSEN C B，GUO L S. Subcutaneous administration of liposomes： a comparison with the intravenous and intraperitoneal routes of injection[J] . Biochim Biophys Acta，1993，1150 (1)：9-16. [29] KIM C K，HAN J H. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats[J] . J Microencapsul，1995，12(4)：437-446. [30] OUSSOREN C，ZUIDEMA J，CROMMELIN D J，et al. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection.-II. Influence of liposomal size，lipid coposition and lipid dose[J] . Biochim Biophys Acta，1997，1328(2)： 261-272. [31] HAWLEY A E，DAVIS S S，ILLUM L. Targeting of colloids to lymph nodes-influence of lymphatic physiology and colloidal characteristics[J] . Adv Drug Deliv Rev，1995，17 (1)：129-148. [32] YANG K，WEN Y M，WANG C M，et al. Clinical application of anticancer nanoparticles targeting metastasis foci of cervical lymph nodes in patients with oral carcinoma[J] . West China J Stomatol(华西口腔医学杂志)，2003，21(6)：447-450. [33] MAINCENT P，THOUVENOT P，AMICABILE C，et al. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats[J] . Pharm Res，1992，9 (12)：1534-1539. [34] HAWLEY A E，ILLUM L，DAVIS S S. Lymph node localization of biodegradable nanospheres surface modified with poloxamer and poloxamine block co polymer[J] . FEBS Lett，1997，400 (3)：319-323. [35] ILLUM L，CHURCH A E，BUTTERWORTH M D. Development of systems for targeting the regional lymph nodes for diagnostic imaging：in vivo behaviour of colloidal PEG-coated magnetite nanospheres in the rat following interstitial administration [J] . Pharm Res，2001，18(5)：640-645. [36] HAWLEY A E，ILLUM L，DAVIS S S. Preparation of biodegradable，surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake[J] . Pharm Res，1997，14 (5) ：657-661. [37] MOGHIMI S M. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres： the effect of the ethylene oxide chain configuration[J] . FEBS Lett，2003，540(1-3)：241-244. [38] LEONG K W，MAO H Q，ROY K，et al. DNA-polycation nanospheres as non-viral gene delivery vehicles[J] . J Controlled Release，1998，53(1-3)：183-193. [39] ROY K，MAO H Q，HUAND S K，et al. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy[J] . Nat Med，1999，5(4)： 387-391. [40] NISHIOKA Y，YOSHINO H. Lymphatic targeting with nanoparticulate system[J] . Adv Drug Deliv Rev，2001，47 (1) ：55-64. [41] NISHIOKA Y，MIZOBE M，YOSHINO H，et al. Evaluation of the lymph-specific delivery using polyisobutylcyanoacrylate nanocapsules：Proceedings of the 118th Annual Meeting of the Pharmaceutical Society of Japan[C] . Kyoto Japan，Vol. 4，1998：51. [42] HE J，FENG J F，CAI B Q，et al. Study on liver targeting effect of silymarin-loaded solid lipid nanoparticles after oral administration[J] . High Technol Lett(高技术通讯)，2005，15(9)：71-75. [43] VIDEIRA M A，BOTELHO M F，SANTOS A C，et al. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles[J] . J Drug Target，2002，10(8)：607-613. [44] MCNEIL S E. Nanotechnology for the biologist[J] . J Leukoc Biol，2005，78(3)：585-594. [45] KOBAYASHI H，KAWAMOTO S，SAKAI Y，et al. Lymphatic drainage imaging of breast cancer in mice by micromagnetic resonance lymphangi-ography using a nano-size paramagnetic contrast agent[J] . J Natl Cancer Inst，2004，96(9)：703-708. [46] SUN L，ZHANG Y G，YANG L Z. Observation of the lymph tissue-targeting property，retention in the abdomen and the distribution of the intraperitoneal activated carbon nano-particles in mice[J] . Bull Acad Mili(Med Sci)(军事医学科学院院刊)，2005，29(4)：349-351. [47] LI C Y，JIANG X H，HOU S X. Studies and applications on lymph targeted drug delivery system[J] . Chin New Drugs J(中国新药杂志)，2001，10(12)：903-907. [48] CAITRIONA M，O'DRISCOL L. Lipid-based formulations for intestinal lymphatic delivery[J] . Eur J Pharm Sci，2002，15 (5) ：405-415. [49] ZHANG J C，LI P X，WANG Y，et al. Study on the preparation of cyclophosphamide microemulsion[J] . Chin J Hosp Pharm(中国医院药学杂志)，2003，23(1)：9-11.